Clinical Trials Lead to New Treatments

At University Hospitals Seidman Cancer Center, our physician-scientists are involved in advancing medicine through research and discovery. With access to myeloma-specific clinical trials, our patients can benefit from innovative therapies, including:

• Minimal residual disease (MRD) detection
• Next generation drugs: Mezigdomide
• Immunotherapy: CAR-T Cells and Monoclonal Antibody

Our team can target treatment based on the most recent innovations in myeloma care. Using these targeted therapies, our patients have access to treatments that are safe and more tolerable.